GS
NTLA icon

GTS Securities’s Intellia Therapeutics NTLA Stock Holding History

GTS Securities’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$139K Buy
+10,834
New +$138K ﹤0.01% 1410
2025
Q4 		– Sell
-23,109
Closed -$399K – 1673
2025
Q3 		$399K Buy
+23,109
New +$285K 0.02% 862

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

GTS Securities's NTLA Position: Q1 2026 in Review

GTS Securities opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 10,834 shares worth $139K. The stake represents ﹤0.01% of the portfolio and ranks #1410 among its holdings. This is a return to the name: GTS Securities previously reported a position in NTLA as recently as Q3 2025.

GTS Securities first reported a position in NTLA in Q3 2025 and has held it in 2 quarters since. The position peaked at $399K in Q3 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • GTS Securities held 10,834 shares of Intellia Therapeutics worth $139K as of Q1 2026.
  • Intellia Therapeutics was a new GTS Securities position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of GTS Securities's portfolio in Q1 2026, its #1410 holding.
  • GTS Securities first reported a position in Intellia Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • GTS Securities's Intellia Therapeutics position peaked at $399K in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.